Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Crown Bioscience Passes 1000 Model Mark in PDX Collection for Oncology Drug Discovery

Published: Wednesday, April 23, 2014
Last Updated: Tuesday, April 22, 2014
Bookmark and Share
Size of collection allows for more informed preclinical decision making on prospective drug candidates.

Crown Bioscience, Inc. has announced its HuPrime® PDX (Patient-Derived Xenograft) model collection has now passed the 1,000 individual models mark.

The HuPrime model collection, many of which are maintained ‘in life’, enable drug discovery companies to run Clinical Trial-like studies, or HuTrials™, using human surrogate models in mice. Such a comprehensive and diverse collection of well characterized models offers pharmaceutical and biotech partners a unique tool to improve the selection and development path for promising clinical candidates. This can significantly accelerate research programs, reducing the costs and failure rates of drug candidate development.

Patient-Derived Xenografts (PDX) involve extracting human tumors tissues directly from patients and transplanting them into surrogate immunodeficient mice. These models enable drug development and discovery companies to identify genetic signatures of disease, and discover and validate predictive biomarkers (HuSignature™) via performing human surrogate Phase II-like trials (HuTrials™).

Crown Bioscience has greatly expanded its capacity maintaining hundred of models live and running 10s of large-scale HuTrial™ efficacy studies in parallel, acquiring results in months, as opposed to years, and at a significantly lower cost compared to standard human clinical trials.

In addition to this unique Mouse Clinical Trial capacity, the accumulated HuTrial™ experience together with newly developed trial design and HuSignature™ algorithms, greatly enhances Crown’s ability to help partners obtain vital preclinical information essential to the success of their key clinical trials. By validating efficacy, studying and understanding mechanisms of action and resistance and identifying biomarkers, it is possible to improve the stratification of patient populations that may benefit from treatment regimens before entering the clinic.

Jean-Pierre Wery, President of Crown Bioscience, comments, “Passing the 1,000 model mark is a significant milestone in our mission to deliver the ‘gold standard’ in well-characterized models and services to help reduce the attrition rate of candidate compounds in the clinic, before they enter the clinic. As drug discovery continues to rapidly evolve, there is a growing desire to screen candidates earlier with more patient-relevant disease models. We believe that through using models which more closely reflect the patient situation in the clinic, we can significantly accelerate our client’s research programs by helping them make better informed decisions about which compounds to progress into clinical trials.”

He continues, “Our comprehensive collection of models is continuing to rapidly expand and evolve, supported by our databases which enable our clients to rapidly identify models which best suit their needs. Screening candidates earlier with more patient-relevant disease models is helping improve the selection of candidates that are taken forward into the clinic. Earlier informed decision making and shorter trials are redefining the cost and success rate in drug development and discovery.”

Crown’s unique database of HuPrime models, HuBase™ offers a comprehensive database of genotypic, pharmacological, and clinical data, allowing clients to identify and choose the models that meet their criteria based on gene expression, RNAseq, copy number, response to Standard of Care, and many other criteria.

Crown Bioscience has a global footprint, spanning three major continents in North America, Europe, and Asia Pacific. The company offers a unique collection of ready-to-run, well-validated in vitro and in vivo models, model development expertise, comprehensive drug discovery platforms, and global capacity to help clients quantify the real efficacy and pharmacological profile of their candidates before they move into the clinic.

As the largest supplier of translational oncology services, Crown Bioscience is committed to providing its pharmaceutical and biopharmaceutical customers with specialized techniques and services to help the world-wide research community turn cancer from an incurable into a manageable, chronic disease and discover new targets and therapies in the treatment of metabolic diseases.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Crown Bioscience Strengthens Immuno-Oncology Capabilities
Company has announced that it has developed and validated a unique set of models for immuno-oncology called HuGEMM™.
Friday, April 15, 2016
Crown Bioscience Expands Cardiovascular and Metabolic Disease Capabilities
Company has announced Zhen Pang as scientific director.
Thursday, October 15, 2015
Crown Bioscience Brings Top Scientists Together
Experts to discuss best approaches to advance translational oncology.
Saturday, October 03, 2015
Crown Bioscience Strengthens Pre-Clinical Leadership Team with Senior Appointment
The company has appointed Laurie Heilmann as senior vice president.
Friday, July 03, 2015
Crown Bioscience Expands its Partnership with The National Resource Center for Mutant Mice
The expanded collaboration will focus on developing immuno-oncology mouse models and other disease-specific experimental models supporting translational medical research.
Friday, July 03, 2015
Crown Bioscience Acquires Molecular Response’s PDX Business
Company is acquiring all of Molecular Response’s existing PDX models.
Friday, February 13, 2015
Crown Bioscience Expands Operations and Re-Brands UK Site
Existing facility will become centre of excellence for hormonal oncology and step up European operations.
Friday, January 09, 2015
Crown Bioscience Announces U.S. Expansion
New service center will allow the expansion of new immunotherapy experimental platforms to advance translational medical research and the treatment of cancers.
Saturday, October 25, 2014
Crown Bioscience President Honored in PharmaVOICE 100
Dr Jean-Pierre Wery is recognized for pioneering work in translational medicine, improving the efficiency of drug discovery and development.
Friday, August 01, 2014
Crown Reveals Strategy for Combined Drug-IR Therapy to Overcome Resistance
Novel strategies for combining drug therapy with irradiation to deliver new hope for overcoming resistance in the clinic.
Saturday, June 21, 2014
Crown Bioscience to Showcase Progression in Human Surrogate Trials
HuTrialTM demonstrates commitment to furthering preclinical understanding in order to improve personal care and increase patient recovery rates.
Wednesday, May 21, 2014
Crown Bioscience Receives $26.55M Series D Funding
Investment will fund rapid expansion in translational platform technologies for oncology and metabolic diseases.
Monday, May 12, 2014
Crown Bioscience Announces Research Collaboration with the NRCMM
New collaboration aims to develop disease-specific experimental models for translational medical research.
Saturday, May 10, 2014
Crown Bioscience Enters Strategic Partnership with SNBL
Agreement’s initial focus is for SNBL to promote Crown services to its Japanese client base.
Friday, April 25, 2014
SIMM and Crown Bioscience Reach Landmark Agreement
Agreement to develop world-leading mouse clinical center and largest annotated PDX and translational oncology platform.
Friday, November 29, 2013
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Researchers Develop Software That Could Facilitate Drug Development
AptaTRACE can identify aptamers, potentially speed drug advancement.
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
New Medication Shows Promise Against Liver Fibrosis in Animal Studies
Liver fibrosis is a gradual scarring of the liver that puts people at risk for progressive liver disease and liver failure.
Raw Eggs Deemed Safe to Eat
A report published today by the Advisory Committee on the Microbiological Safety of Food (ACMSF) into egg safety has shown a major reduction in the risk from salmonella in UK eggs.
Monitoring TTX Toxin in Shellfish
In a number of small studies, mussels and oysters from the eastern and northern part of the Oosterschelde in Holland were found to contain tetrodotoxin (TTX).
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!